Endoscopic bariatric and metabolic therapies for non-alcoholic fatty liver disease: Evidence and perspectives

Federico Salomone, Reem Z. Sharaiha, Ivo Boskoski

Risultato della ricerca: Contributo in rivistaArticolo in rivista

10 Citazioni (Scopus)


Non-alcoholic fatty liver disease (NAFLD) has become the most common liver disease in industrialized countries because of the worldwide epidemic of obesity. Beyond metabolic complications, a subset of patients with NAFLD develop non-alcoholic steatohepatitis (NASH) with fibrosis, which is emerging as a leading cause of liver transplantation due to progression to cirrhosis and cancer. For these reasons, NAFLD is considered a public health burden. In recent years endoscopic bariatric and metabolic therapies (EBMT) have emerged as safe and effective for the treatment of obesity and type 2 diabetes mellitus. EBMT include gastric and duodenal devices and techniques such as intragastric balloons, endoscopic sleeve gastroplasty, endoscopic small bowel by-pass and duodenal mucosal resurfacing. Observational studies and pilot trials have revealed beneficial effects of EBMT on NAFLD as assessed by non-invasive parameters or histology. In this review we summarise current evidence for the efficacy and safety of EBMT in obese patients with NAFLD and examine future clinical applications.
Lingua originaleEnglish
pagine (da-a)1262-1268
Numero di pagine7
RivistaLiver International
Stato di pubblicazionePubblicato - 2020


  • bariatric endoscopy
  • duodenal mucosal resurfacing
  • endoscopic sleeve gastroplasty
  • intragastric balloon
  • obesity


Entra nei temi di ricerca di 'Endoscopic bariatric and metabolic therapies for non-alcoholic fatty liver disease: Evidence and perspectives'. Insieme formano una fingerprint unica.

Cita questo